Share This Author
A lethal disease model for hantavirus pulmonary syndrome.
The characteristics of the disease in hamsters, including the incubation period, symptoms of rapidly progressing respiratory distress, and pathologic findings of pulmonary edema and pleural effusion, closely resemble HPS in humans.
Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal Monkeypox
This is the first demonstration that a subunit vaccine approach to smallpox-monkeypox immunization is feasible and it is demonstrated that rhesus macaques vaccinated with a DNA vaccine consisting of four vaccinia virus genes were protected from severe disease after an otherwise lethal challenge with monkeypox virus.
Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
The results indicated that vaccination with both L1R and A33R proteins, intended to evoke mechanistically distinct and complementary forms of protection, was more effective than vaccination with either protein by itself.
Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox virus
It is reported that vaccinia-specific B-cell responses are essential for protection of macaques from monkeypox virus, a variola virus ortholog, and vaccines able to induce long-lasting protective antibody responses may constitute realistic alternatives to the currently available smallpox vaccine.
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
RVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy, and glycoprotein-binding antibody titers were sustained through 180 days in all participants.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
This Ebola vaccine candidate elicited anti‐Ebola antibody responses and these results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses.
Treatment of hantavirus pulmonary syndrome.
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Temporal Analysis of Andes Virus and Sin Nombre Virus Infections of Syrian Hamsters
Treatment strategies aimed at preventing virus replication and dissemination will have the greatest probability of success if administered before the viremic phase of hantavirus pulmonary syndrome, however, because vascular leakage is associated with infected endothelial cells, a therapeutic strategy targeting viral replication might be effective even at later times.